Mazindol ER (NLS-4 / Quilience®)
Narcolepsy (Type 1 & 2)
Key Facts
Indication
Narcolepsy (Type 1 & 2)
Phase
Phase 3
Status
Active (Pivotal program planned)
Company
About NLS Pharmaceutics
NLS Pharmaceutics is a clinical-stage biotech focused on developing improved therapeutics for CNS disorders, particularly narcolepsy. Its core strategy involves the repurposing and reformulation of known pharmacologic agents to enhance efficacy, duration, and tolerability. The company's lead asset, Mazindol ER (NLS-4/Quilience®), has demonstrated promising Phase 2 results for narcolepsy and is advancing into a pivotal Phase 3 program. Operating as a lean, virtual organization, NLS aims to efficiently navigate clinical development and address high-value market opportunities with limited treatment options.
View full company profile